E
Leap Therapeutics, Inc.
LPTX
$0.2785
-$0.0137-4.69%
E
Sell
3/24/2025Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 3/24/2025 due to a decline in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 3/24/2025 due to a decline in the total return index and volatility index.
D
Sell
3/7/2025Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 3/7/2025 due to an increase in the volatility index.
E
Sell
2/19/2025Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 2/19/2025 due to a noticeable decline in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 2/19/2025 due to a noticeable decline in the total return index and volatility index.
D
Sell
1/29/2025Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 1/29/2025 due to an increase in the volatility index and valuation index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 1/29/2025 due to an increase in the volatility index and valuation index.
E
Sell
1/13/2025Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 1/13/2025 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 5.08 to 3.95.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 1/13/2025 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 5.08 to 3.95.
D
Sell
2/12/2024Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 2/12/2024 due to an increase in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 2/12/2024 due to an increase in the total return index and volatility index.
E
Sell
1/26/2024Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
D
Sell
1/4/2024Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the solvency index and volatility index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the solvency index and volatility index.
E
Sell
3/14/2023Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 03/14/2023.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 02/23/2023.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
1/5/2023Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 1/5/2023 due to a decline in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 1/5/2023 due to a decline in the total return index and volatility index.
D
Sell
12/21/2022Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index.
D
Sell
12/6/2022Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 12/6/2022 due to a decline in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 12/6/2022 due to a decline in the total return index and volatility index.
D
Sell
11/21/2022Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 11/21/2022 due to an increase in the total return index, growth index and valuation index. Earnings per share increased from -$0.1503 to -$0.1333, EBIT increased 10.28% from -$16.31M to -$14.64M, and operating cash flow increased 0.05% from -$12.26M to -$12.25M.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 11/21/2022 due to an increase in the total return index, growth index and valuation index. Earnings per share increased from -$0.1503 to -$0.1333, EBIT increased 10.28% from -$16.31M to -$14.64M, and operating cash flow increased 0.05% from -$12.26M to -$12.25M.
D
Sell
8/1/2022Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 8/1/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 7.48% from -$10.72M to -$11.52M.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 8/1/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 7.48% from -$10.72M to -$11.52M.
D
Sell
5/5/2022Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 05/05/2022.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D+ on 4/20/2022 due to a substantial decline in the total return index.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D+ on 4/20/2022 due to a substantial decline in the total return index.
D
Sell
11/17/2021Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D+ from D on 11/17/2021 due to an increase in the valuation index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D+ from D on 11/17/2021 due to an increase in the valuation index.
D
Sell
11/15/2021Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 11/15/2021 due to a large increase in the solvency index, valuation index and total return index. The quick ratio increased from 4.44 to 11.09, and debt to equity declined from 0.01 to 0.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 11/15/2021 due to a large increase in the solvency index, valuation index and total return index. The quick ratio increased from 4.44 to 11.09, and debt to equity declined from 0.01 to 0.
D
Sell
11/8/2021Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, volatility index and total return index.
Leap Therapeutics, Inc. (LPTX) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, volatility index and total return index.
C
Hold
4/27/2020Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to C- from D+ on 4/27/2020 due to a noticeable increase in the total return index and volatility index.
Leap Therapeutics, Inc. (LPTX) was upgraded to C- from D+ on 4/27/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/17/2020Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D+ from D on 3/17/2020 due to a significant increase in the efficiency index, valuation index and total return index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D+ from D on 3/17/2020 due to a significant increase in the efficiency index, valuation index and total return index.
D
Sell
2/18/2020Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 2/18/2020 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.3652 to -$0.3317, EBIT increased 5.6% from -$8.4M to -$7.93M, and operating cash flow increased 3.15% from -$7.18M to -$6.96M.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 2/18/2020 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.3652 to -$0.3317, EBIT increased 5.6% from -$8.4M to -$7.93M, and operating cash flow increased 3.15% from -$7.18M to -$6.96M.
D
Sell
5/31/2019Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 5/31/2019 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.3713 to -$0.4659.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 5/31/2019 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.3713 to -$0.4659.
D
Sell
4/23/2019Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 4/23/2019 due to an increase in the valuation index, growth index and solvency index. Earnings per share increased from -$0.5538 to -$0.3713, and operating cash flow increased 5.39% from -$7.45M to -$7.05M.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 4/23/2019 due to an increase in the valuation index, growth index and solvency index. Earnings per share increased from -$0.5538 to -$0.3713, and operating cash flow increased 5.39% from -$7.45M to -$7.05M.
D
Sell
11/30/2018Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 11/30/2018 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 5.22 to 4.
Leap Therapeutics, Inc. (LPTX) was downgraded to D- from D on 11/30/2018 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 5.22 to 4.
D
Sell
2/21/2018Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 2/21/2018 due to an increase in the volatility index and total return index.
Leap Therapeutics, Inc. (LPTX) was upgraded to D from D- on 2/21/2018 due to an increase in the volatility index and total return index.
D
Sell
10/2/2017Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E on 10/2/2017 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.3905 to -$0.7352, and EBIT increased 33.52% from -$9.81M to -$6.52M.
Leap Therapeutics, Inc. (LPTX) was upgraded to D- from E on 10/2/2017 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.3905 to -$0.7352, and EBIT increased 33.52% from -$9.81M to -$6.52M.
E
Sell
7/5/2017Upgraded
Leap Therapeutics, Inc. (LPTX) was upgraded to E from E- on 07/05/2017.
Leap Therapeutics, Inc. (LPTX) was upgraded to E from E- on 07/05/2017.
E
Sell
6/7/2017Downgrade
Leap Therapeutics, Inc. (LPTX) was downgraded to E- from E on 6/7/2017 due to a noticeable decline in the volatility index.
Leap Therapeutics, Inc. (LPTX) was downgraded to E- from E on 6/7/2017 due to a noticeable decline in the volatility index.
E
Sell
4/20/2017None
Leap Therapeutics, Inc. (LPTX) was downgraded to E from U on 04/20/2017.
Leap Therapeutics, Inc. (LPTX) was downgraded to E from U on 04/20/2017.
NASDAQ
04/08/2025 11:01AM Eastern
Quotes delayed
